Jarred Younger, PhD - The Ten Most Important Fibromyalgia Discoveries of 2016 and 2017 (2017 Conference) (LDN, low dose naltrexone)
People with rheumatological conditions are much more likely to have fibromyalgia than the general population, Lupus in particular was indicated to be the most likely rheumatological condition where fibromyalgia was also present.
Chronically elevated C-Reactive protein is associated with a higher risk of fibromyalgia diagnosis.
Fractalkine in cerebrospinal fluid is elevated in fibromyalgia.
Excess glutamate in the brain is associated with fibromyalgia.
MicroRNA describes fibromyalgia pathology.
Effects of Vitamin D therapy on quality of life in patients with fibromyalgia.
Low Dose Naltrexone (LDN) reduces several pro-inflammatory cytokines in fibromyalgia.
Famciclovir and celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia.
Ambroxol is a novel treatment approach for fibromyalgia.
Low frequency magnetic fields reduce fibromyalgia pain.
These are the ten studies that Dr Younger discusses.
In the low dose naltrexone study Dr Jarrod says that low dose naltrexone seems to work really well for patients with fibromyalgia, but when they tried to get additional funding from federal sources the biggest question is “Why can’t you show us how it works in the people? We want to see the mechanism before we can fully believe this”. Dr Younger says there are a lot of possible ways that low dose naltrexone works and there are multiple true ways that it has clinical impact. So his study was done to show that it is a systemic anti-inflammatory, a lot of the pro-inflammatory cytokines show a clear linear decrease the longer somebody was on low dose naltrexone. The results show that low dose naltrexone is associated clearly with the improvement in symptoms.
For more presentations please visit https://ldnresearchtrust.org/ldn-conferences